CS-231295

N/A

Report date: 2025/08/04 17:39:59
NME

Base Information

Drug NameCS-231295
Drug Alias NameCS-231295CS231295
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinases inhibitors
TargetsProtein kinases
Therapy Area/IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Chipscreen Biosciences Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChipscreen Biosciences (USA) LtdShenzhen Weixin Pharmaceutical Co LtdShenzhen Chipscreen Biosciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesSolid tumoursSmall Cell Lung Carcinoma +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A